Treatment costs are shared between the patient, the pharmaceutical company, and potentially other parties, based on a patient’s ability to pay. Unlike bonus schemes, cost sharing enables patients to access their full course of treatment, and in turn, maximize their medical outcomes.
Many patients don’t have the liquidity to pay for the medication cost up front, even those that may be reimbursed. They may be waiting for reimbursement or be able to pay in smaller increments. By offering a credit line, patients are able to access treatment immediately, and repay the amount once the funds become available.
For patients who are partially reimbursed, some still struggle to cover the non-reimbursed co-pay for their medication. By supporting these patients by covering their co-pay via voucher, they are able to complete their full course of treatment as prescribed.
The above are examples of innovative access models used by Axios. At the stage of strategy development, the specific needs of a given patient group, country, product and disease area are considered to design customized access models to close the identified gaps.